Company intelligence / Profile preview

Advanced Cell Therapy and Research Institute, Singapore

Singapore, Singaporeactris.sg ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

ACTRIS is Singapore’s national center of excellence for the discovery, process development, manufacturing, and clinical translation of cellular-based therapeutics. It supports the entire value chain from R&D to commercialization across immunotherapy and regenerative medicine. The institute provides GMP-compliant facilities/services but does not sponsor its own drug candidates or publish clinical results under its own name[2][3][7].

Therapeutic areas: OtherImmunology
Modalities: Cell therapyGene therapyInduced pluripotent stem cell derived therapy (implied by focus on cellular-based therapeutics)
Industry: Academic Hospital/University/Research

Partnerships

Agilent Technologies Inc.

Beyond the preview

Go deeper on Advanced Cell Therapy and Research Institute, Singapore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Cell Therapy and Research Institute, Singapore.

Explore the full profile